Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study DOI Creative Commons
Chao Jing, Zhigang Bai, Kuinan Tong

et al.

The Oncologist, Journal Year: 2024, Volume and Issue: 29(11), P. e1565 - e1574

Published: Aug. 5, 2024

Abstract Background Biliary tract cancer (BTC) is a highly malignant tumor, with limited therapy regimens and short response duration. In this study, we aim to assess the efficacy safety of combination camrelizumab, apatinib, capecitabine as first- or second-line treatment in patients advanced BTC. Methods phase 2, nonrandomized, prospective eligible received camrelizumab (200 mg, d1, Q3W), apatinib (250 qd, d1-d21, (1000 mg/m², bid, d1-d14, Q3W) until trial discontinued. The primary endpoint was objective rate (ORR). secondary endpoints were disease control rate, progression-free survival (PFS), overall (OS), safety. Results From July 2019 April 2023, enrolled total 28 patients, whom 14 first-line setting setting. At data cutoff (April 30, 2023), median follow-up duration 18.03 months. Eight reached (ORR: 28.57%), an ORR 50% 7.1% for (P = .033). PFS 6.30 months OS 12.80 Grade 3 4 adverse events (AEs) occurred 9 (32.14%) including elevated transaminase, thrombocytopenia, etc. No serious treatment-related AEs deaths occurred. Conclusions trial, showed promising antitumor activity manageable toxicity BTC, especially Clinical Trial Registration NCT04720131.

Language: Английский

Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions DOI
Yibei Wang, Mohammed Safi, Fred R. Hirsch

et al.

Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: 22(3), P. 200 - 214

Published: Jan. 6, 2025

Language: Английский

Citations

1
Association between platelet-to-lymphocyte ratio and immune checkpoint inhibitor-induced thyroid dysfunction DOI

Wang Ai,

Huijie Huang,

Yangli Chen

et al.

Endocrine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

Language: Английский

Citations

0
Optimizing Cancer Treatment Through Gut Microbiome Modulation DOI Open Access

Kyuri Kim,

Mingyu Lee,

Yoojin Shin

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(7), P. 1252 - 1252

Published: April 7, 2025

The gut microbiome plays a pivotal role in modulating cancer therapies, including immunotherapy and chemotherapy. Emerging evidence demonstrates its influence on treatment efficacy, immune response, resistance mechanisms. Specific microbial taxa enhance checkpoint inhibitor while dysbiosis can contribute to adverse outcomes. Chemotherapy effectiveness is also influenced by composition, with engineered probiotics prebiotics offering promising strategies drug delivery reduce toxicity. Moreover, metabolites, such as short-chain fatty acids, systems have shown potential improve therapeutic responses. These findings underscore the importance of personalized microbiome-based approaches optimizing treatments.

Language: Английский

Citations

0
Scleroderma-like Lesions in a Patient Undergoing Combined Pembrolizumab and Routine Chemotherapy: A Case Report and Literature Review DOI Creative Commons
Hung‐Liang Pai,

Chin-Yin Liu,

Ming‐Hsin Yeh

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(7), P. 1092 - 1092

Published: July 3, 2024

Triple-negative breast cancer (TNBC) represents a challenging malignancy with limited treatment options and poor prognosis. Adjuvant therapies, including chemotherapy immune checkpoint inhibitors (ICI), are commonly employed following conservation surgery. However, these treatments can lead to various adverse effects, cutaneous complications connective tissue disorders. Here, we present the case of 54-year-old woman TNBC who developed morphea, form localized scleroderma, adjuvant pembrolizumab administration. This highlights rarity drug-induced morphea emphasizes importance recognizing managing such events in patients. We discuss clinical characteristics, diagnostic challenges, considerations associated scleroderma-like lesions, as well potential mechanisms underlying their development. Furthermore, review literature on incidence, features, outcomes lesions induced by ICIs. underscores need for increased awareness immune-related patients receiving immunotherapy, individualized approaches optimize patient care outcomes.

Language: Английский

Citations

1
Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease DOI Creative Commons
Saedís Saevarsdóttir,

Kristbjörg Bjarnadóttir,

Thorsteinn Markusson

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: July 9, 2024

Abstract Autoimmune thyroid disease (AITD) is a common autoimmune disease. In GWAS meta-analysis of 110,945 cases and 1,084,290 controls, 290 sequence variants at 225 loci are associated with AITD. Of these variants, 115 previously unreported. Multiomics analysis yields 235 candidate genes outside the MHC-region findings highlight importance involved in T-cell regulation. A rare 5’-UTR variant (rs781745126-T, MAF = 0.13% Iceland) LAG3 has largest effect (OR 3.42, P 2.2 × 10 −16 ) generates novel start codon for an open reading frame upstream canonical protein translation initiation site. rs781745126-T reduces mRNA surface expression inhibitory immune checkpoint LAG-3 co-receptor on activated lymphocyte subsets halves levels plasma among heterozygotes. All three homozygous carriers have AITD, whom one also two other mediated diseases, that vitiligo type 1 diabetes. associates nominally 5.1, 6.5 −3 but not Thus, akin to drugs inhibit LAG-3, which unleash responses can dysfunction as adverse events. This illustrates how multiomics approach reveal potential drug targets safety concerns.

Language: Английский

Citations

1
The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance DOI Creative Commons
Filomena Russo, Anna Pira, Feliciana Mariotti

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 29, 2024

Bullous pemphigoid (BP) is the most common autoimmune bullous disease: it commonly affects individuals over 70 years old and impacts severely on their quality of life. BP represents a paradigm for an organ-specific disease characterized by circulating IgG autoantibodies to hemidesmosomal components: BP180 BP230. While crucial role these in triggering inflammatory cascade fully acknowledged, many ancillary etiological mechanisms need be elucidated yet. Cutaneous melanoma due malignant transformation skin melanocytes, that produce distribute pigments surrounding keratinocytes. Melanoma fatal cancer because its increasing incidence propensity metastasize. Several data such as: i) reported cases concomitant BP; ii) results from association studies; iii) onset following immune check-point inhibitors therapy; iv) expression antigens transformed melanocytes; vi) patients suggest intriguing, although unproven, possible between BP. However, causative link still debated putative pathogenetic mechanism underlying this unclear. This review aims describe discuss relationship give overview speculations or against association. Of note, if demonstrated, could unwrap considerations clinical relevance represent new research frontiers.

Language: Английский

Citations

1
Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study DOI Creative Commons
Chao Jing, Zhigang Bai, Kuinan Tong

et al.

The Oncologist, Journal Year: 2024, Volume and Issue: 29(11), P. e1565 - e1574

Published: Aug. 5, 2024

Abstract Background Biliary tract cancer (BTC) is a highly malignant tumor, with limited therapy regimens and short response duration. In this study, we aim to assess the efficacy safety of combination camrelizumab, apatinib, capecitabine as first- or second-line treatment in patients advanced BTC. Methods phase 2, nonrandomized, prospective eligible received camrelizumab (200 mg, d1, Q3W), apatinib (250 qd, d1-d21, (1000 mg/m², bid, d1-d14, Q3W) until trial discontinued. The primary endpoint was objective rate (ORR). secondary endpoints were disease control rate, progression-free survival (PFS), overall (OS), safety. Results From July 2019 April 2023, enrolled total 28 patients, whom 14 first-line setting setting. At data cutoff (April 30, 2023), median follow-up duration 18.03 months. Eight reached (ORR: 28.57%), an ORR 50% 7.1% for (P = .033). PFS 6.30 months OS 12.80 Grade 3 4 adverse events (AEs) occurred 9 (32.14%) including elevated transaminase, thrombocytopenia, etc. No serious treatment-related AEs deaths occurred. Conclusions trial, showed promising antitumor activity manageable toxicity BTC, especially Clinical Trial Registration NCT04720131.

Language: Английский

Citations

0